| HOME >> BIOLOGY >> TECHNOLOGY |
MOUNTAIN VIEW, Calif., July 9 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that Christopher Kurtz has joined the company as Vice President, Global Supply Chain and Sustainment Engineering. He will have primary responsibilities in the development and execution of Alexza's global supply chain strategy to support the commercialization of Alexza's pipeline of clinical product candidates. Alexza's lead program, AZ-004 (Staccato(R) loxapine) is in Phase 3 clinical testing for the treatment of acute agitation in schizophrenic or bipolar disorder patients.
Mr. Kurtz was most recently Vice President of Research and Development and Director, Pharmaceutical Manufacturing and Development for Novo Nordisk Delivery Technologies, Hayward, California. Prior to his tenure at Novo, Mr. Kurtz held positions as Senior Director, Process Engineering for ALZA Corporation, a division of Johnson and Johnson from January to June 2006. He was previously Director, Operations Engineering and Director Manufacturing Engineering for Nektar Therapeutics, San Carlos, California from January 2001 to January 2006 and also held previous positions at PowderJect Pharmaceuticals, PLC and Monsanto, Inc. Mr. Kurtz holds a Bachelor of Science degree in Chemical Engineering and Chemistry from University of Colorado at Boulder.
"We are very pleased to welcome Christopher to Alexza and as a member of our Executive Team," said Michael Simms, Senior Vice President, Operations and Manufacturing. "His broad experience in working with external manufacturing partners to develop, scale-up and launch drug delivery-based products will be instrumental as Alexza rapidly moves toward commercialization of its pipeline."
Alexza Pharmace
'/>"/>
| SOURCE Alexza Pharmaceuticals, Inc. Copyright©2008 PR Newswire. All rights reserved |